# Eyebot

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eyebot

- Industry: Healthcare Specialists
- Headquarters: Boston, US
- Website: www.eyebot.co/
- Total disclosed funding: $30M
- Latest round: Series A (Jul 1, 2025)
- Investors on record: 7

## About

Based in Massachusetts, US, and founded in 2021 by CEO Matthias Hofmann and CTO Jack Moldave, 123 See, Inc., d.b.a. Eyebot, operates as a healthcare technology company that focuses on providing rapid eye testing systems that eliminate the barriers to obtaining vision care. The company provides rapid eye testing technologies that ensure precise and fast results, making vision testing accessible to everyone. Its fully automated, freestanding units are adaptable to store branding, providing a seamless customer experience. In August 2025, Eyebot raised USD 21.98 million in seed funding led by General Catalyst Partners, with participation from AlleyCorp, Baukunst, Ubiquity Ventures, and Village Global. The company plans to utilize the August 2025 funding for vision test kiosk deployment, clinical team expansion, engineering team expansion, and eye care professional engagement infrastructure.

## Funding rounds

- Series A, Jul 1, 2025, $22M — General Catalyst Partners, Ubiquity Ventures, Village Global, AlleyCorp, Baukunst, Humba Ventures
- Seed, Apr 26, 2024, $8.3M — Ubiquity Ventures, Village Global, AlleyCorp, Spacecadet Ventures, Baukunst, Humba Ventures

## Investors

- Ubiquity Ventures (https://capitalatlas.ai/funds/ubiquity-ventures) — Seed, Series A
- Village Global (https://capitalatlas.ai/funds/village-global) — Seed, Series A
- AlleyCorp — Seed, Series A
- Spacecadet Ventures (https://capitalatlas.ai/funds/spacecadet-ventures) — Seed
- Baukunst (https://capitalatlas.ai/funds/baukunst) — Seed, Series A
- Humba Ventures — Seed, Series A
- General Catalyst Partners (https://capitalatlas.ai/funds/general-catalyst-partners) — Series A